148 related articles for article (PubMed ID: 8993520)
21. Chemotherapy for small cell lung cancer.
Sandler AB
Semin Oncol; 2003 Feb; 30(1):9-25. PubMed ID: 12635086
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Kudelka AP; Tresukosol D; Edwards CL; Freedman RS; Levenback C; Chantarawiroj P; Gonzalez de Leon C; Kim EE; Madden T; Wallin B; Hord M; Verschraegen C; Raber M; Kavanagh JJ
J Clin Oncol; 1996 May; 14(5):1552-7. PubMed ID: 8622071
[TBL] [Abstract][Full Text] [Related]
23. Topotecan approved for cancer chemotherapy.
Am J Health Syst Pharm; 1996 Aug; 53(15):1763-4. PubMed ID: 8842305
[No Abstract] [Full Text] [Related]
24. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
[TBL] [Abstract][Full Text] [Related]
25. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Bonneterre J
Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
[TBL] [Abstract][Full Text] [Related]
26. Topotecan: an important new drug in the management of ovarian cancer.
Markman M
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-1. PubMed ID: 9122736
[No Abstract] [Full Text] [Related]
27. Topotecan hydrochloride for metastatic ovarian cancer.
Med Lett Drugs Ther; 1996 Oct; 38(986):96-7. PubMed ID: 8906133
[No Abstract] [Full Text] [Related]
28. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
[TBL] [Abstract][Full Text] [Related]
29. [Irinotecan].
Yokoyama A
Nihon Rinsho; 2002 May; 60 Suppl 5():339-42. PubMed ID: 12101684
[No Abstract] [Full Text] [Related]
30. Evolving role of topotecan in treating small-cell lung cancer.
Reddy K
Clin Lung Cancer; 2004 Mar; 5(5):270-2. PubMed ID: 15086965
[No Abstract] [Full Text] [Related]
31. FDA approve bark-derived drug.
Barnett AA
Lancet; 1996 Jun; 347(9015):1613. PubMed ID: 8667876
[No Abstract] [Full Text] [Related]
32. Topotecan: a review of its efficacy in small cell lung cancer.
Ormrod D; Spencer CM
Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
[TBL] [Abstract][Full Text] [Related]
33. Emerging role of topotecan in front-line treatment of carcinoma of the ovary.
Coleman RL
Oncologist; 2002; 7 Suppl 5():46-55. PubMed ID: 12324633
[TBL] [Abstract][Full Text] [Related]
34. [Topoisomerase I inhibitor with potential radiosensitizing effect].
Sauer R; Heuser A
Strahlenther Onkol; 1997 Mar; 173(3):125-30. PubMed ID: 9122851
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase I inhibitors: topotecan and irinotecan.
Jones SF; Burris HA
Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772
[No Abstract] [Full Text] [Related]
36. Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?
Rowinsky EK
Oncologist; 2002; 7(4):324-30. PubMed ID: 12185294
[TBL] [Abstract][Full Text] [Related]
37. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Ardizzoni A; Hansen H; Dombernowsky P; Gamucci T; Kaplan S; Postmus P; Giaccone G; Schaefer B; Wanders J; Verweij J
J Clin Oncol; 1997 May; 15(5):2090-6. PubMed ID: 9164222
[TBL] [Abstract][Full Text] [Related]
38. Topotecan in the treatment of gynecologic cancer.
Coleman RL; Miller DS
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
[TBL] [Abstract][Full Text] [Related]
39. [Current status of phase I and phase II trials--experience in Habikino from 1988 to 1994].
Masuda N; Negoro S; Fukuoka M
Gan To Kagaku Ryoho; 1996 Jan; 23(2):166-71. PubMed ID: 8611044
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
Seiden MV; Muggia F; Astrow A; Matulonis U; Campos S; Roche M; Sivret J; Rusk J; Barrett E
Gynecol Oncol; 2004 Apr; 93(1):229-32. PubMed ID: 15047241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
